1092 |
6836-442 |
Safer |
Hydrogen peroxide |
DS6835 |
Arxada, LLC |
Healthcare; Institutional |
Hard Nonporous (HN) |
0.5 minutes |
Ready-to-use; Electrostatic Spray |
SARS-CoV-2 |
2021-04-13 |
Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1438 |
6836-277 |
Increased Risk |
Quaternary ammonium |
BARDAC 205M-1.30 |
Arxada, LLC |
Healthcare; Institutional; Residential |
Hard Nonporous (HN) |
10.0 minutes |
Dilutable; Electrostatic Spray |
Norovirus |
2020-03-13 |
Kills a harder-to-kill pathogen than SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1439 |
6836-303 |
Increased Risk |
Quaternary ammonium |
BARDAC 205M-5.2 |
Arxada, LLC |
Healthcare; Institutional; Residential |
Hard Nonporous (HN) |
10.0 minutes |
Dilutable; Electrostatic Spray |
Norovirus |
2020-03-13 |
Kills a harder-to-kill pathogen than SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1449 |
87742-1 |
Safer |
Thymol |
Thymox Disinfectant Spray |
Laboratorie M2 |
Healthcare; Institutional; Residential |
Hard Nonporous (HN); Food Contact No Rinse (FCNR) |
1.0 minutes |
Ready-to-use; Electrostatic Spray |
SARS-CoV-2 |
2021-01-28 |
Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1478 |
6836-266 |
Increased Risk |
Quaternary ammonium |
BARDAC 205M-10 |
Arxada, LLC |
Healthcare; Institutional; Residential |
Hard Nonporous (HN); Food Contact Post-Rinse Required (FCR) |
10.0 minutes |
Dilutable; Electrostatic Spray |
Norovirus |
2020-03-03 |
Kills a harder-to-kill pathogen than SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1479 |
6836-278 |
Increased Risk |
Quaternary ammonium |
BARDAC 205M- 14.08 |
Arxada, LLC |
Healthcare; Institutional; Residential |
Hard Nonporous (HN) |
10.0 minutes |
Dilutable; Electrostatic Spray |
Norovirus |
2020-03-03 |
Kills a harder-to-kill pathogen than SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1480 |
6836-289 |
Increased Risk |
Quaternary ammonium |
BARDAC 205M RTU |
Arxada, LLC |
Healthcare; Institutional; Residential |
Hard Nonporous (HN); Food Contact Post-Rinse Required (FCR) |
10.0 minutes |
Ready-to-use; Electrostatic Spray |
Norovirus |
2020-03-03 |
Kills a harder-to-kill pathogen than SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1481 |
6836-302 |
Increased Risk |
Quaternary ammonium |
BARDAC 205M-2.6 |
Arxada, LLC |
Healthcare; Institutional; Residential |
Hard Nonporous (HN); Food Contact Post-Rinse Required (FCR) |
10.0 minutes |
Dilutable; Electrostatic Spray |
Norovirus |
2020-03-03 |
Kills a harder-to-kill pathogen than SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1482 |
6836-305 |
Increased Risk |
Quaternary ammonium |
BARDAC 205M-23 |
Arxada, LLC |
Healthcare; Institutional; Residential |
Hard Nonporous (HN); Food Contact Post-Rinse Required (FCR) |
10.0 minutes |
Dilutable; Electrostatic Spray |
SARS-CoV-2 |
2020-03-03 |
Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1486 |
6836-70 |
Increased Risk |
Quaternary ammonium |
BARDAC 205M-7.5 |
Arxada, LLC |
Healthcare; Institutional; Residential |
Hard Nonporous (HN) |
10.0 minutes |
Dilutable; Electrostatic Spray |
Norovirus |
2020-03-03 |
Kills a harder-to-kill pathogen than SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1493 |
71847-6 |
Increased Risk |
Sodium dichloroisocyanurate |
Klorsept |
Medentech LTD |
Healthcare; Institutional; Residential |
Hard Nonporous (HN) |
1.0 minutes |
Dilutable; Electrostatic Spray |
SARS-CoV-2 |
2021-01-28 |
Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |
1494 |
71847-7 |
Increased Risk |
Sodium dichloroisocyanurate |
Klorkleen |
Medentech LTD |
Healthcare; Institutional; Residential |
Hard Nonporous (HN) |
4.0 minutes |
Dilutable; Electrostatic Spray |
SARS-CoV-2 |
2021-01-28 |
Tested against SARS-CoV-2 (COVID-19); Emerging viral pathogen claim |